小鼠腹水型肝癌细胞对竹红菌乙素的摄取和滞留

采用 SDS 胶束增溶法较详细地研究了小鼠腹水型肝癌细胞对竹红菌乙素的摄取和滞留过程.从实验结果表明:a.细胞摄取乙素与弗伦德里希吸附等温式符合较好,细胞的饱和吸附量为每个细胞吸附1.23×10⁸乙素分子.b.摄取速度很快,37℃下3min 即可达到饱和.c.被细胞摄取的乙素较难重新释放到溶液,而且未发生明显代谢变化.d.血清可携带乙素在细胞间传递.e.乙素趋向于进入细胞膜双分子层的深处.还结合实验结果对所采用的 SDS 胶束增溶法进行了评述.     

姜黄素对两株不同转移力小鼠腹水型肝癌细胞生物学特性的影响

目的 研究姜黄素（Curcumin,Cur）对来源于同一亲本的小鼠腹水型肝癌高、低淋巴道转移株（HCa-F和HCa-P）增殖、细胞周期分布及皮下移植HCa-F和HCa-P的615小鼠生存期的影响,并探讨2株细胞对Cur的敏感性差异是否存在显著性.方法 用15～250 μmol/L Cur分别处理HCa-F和HCa-P 48 h,以MTT法检测细胞的生长活性,以生长曲线评估药物对细胞生长的作用,以流式细胞仪检测药物对细胞周期分布的影响,观察Cur对细胞形态的影响.给615小鼠右腋中线皮下接种HCa-F和HCa-P细胞,通过ig给药的方法,观察Cur对荷瘤鼠生存期的影响.结果 Cur可抑制HCa-F和HCa-P的生长,抑制率分别为7.23%～82.23%和6.04%～61.31%,且呈剂量依赖性;IG0在HCa-F为51.48μmol/L,在HCa-P为90.87μmol/L;在非细胞毒性最大剂量15μmol/L Cur作用下,2株细胞的生长速度均受到抑制,群体倍增时间延长;HCa-F细胞形态受到影响;细胞周期被重新分布,HCa-F被阻滞在S期,HCa-P被阻滞于S期和G2/M期.经ig给予150 mg/kg的Cur可使皮下接种HCa-F和HCa-P的615小鼠生存率提高分别达45.06%和49.68%.结论 Cur可抑制HCa-F和HCa-P的增殖,使细胞周期重新分布,且高转移细胞株HCa-F较低转移细胞株HCa-P对Cur更为敏感Cur可延长荷瘤鼠的生存期.     

5- 脱氧杂氮胞苷对人肝癌细胞HepG2 增殖及beclin1 表达的影响

目的:观察5-脱氧杂氮胞苷(5-aza-CdR)对HepG2细胞生长抑制及beclin1表达的影响,以探讨其抗肿瘤发生的潜在机制。方法:采用四甲基偶氮唑盐(MTT)法检测5-aza-CdR对HepG2细胞的生长抑制;用相差显微镜观察不同药物浓度下不同时间段的肝癌细胞形态学改变;采用RT-PCR法和Western blot法检测5-Aza-CdR对抑癌基因beclin1的mRNA和蛋白表达的影响。结果:5-aza-CdR可抑制HepG2细胞生长,呈剂量依赖性,并上调beclin1的mRNA和蛋白的表达。结果:显示102.4umol/L5-aza-C-dR作用72小时细胞增殖抑制率最高,可达(84.3±3.31)%,beclin1的mRNA和蛋白表达上调最明显,与对照组相比差异有统计学意义。结论:5-aza-CdR可抑制HepG2细胞增殖,其机制可能是通过恢复某些抑癌基因的表达,上调beclin1的mRNA和蛋白表达。     

丹酚酸B对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响

摘要 目的：探讨丹酚酸B(salvianolic acid B,Sal B)对肝癌荷瘤小鼠抑瘤作用及对肝纤维化的影响。方法：将HepG2肝癌细胞株皮下注射于裸鼠左腋下成瘤,将荷瘤小鼠(n=42)随机平分为三组：模型组、Sal B 1组与Sal B 2组。Sal B 1组与Sal B 2组于造模成功当天开始分别给予10 mL/kg/d和15 mL/kg/d丹酚酸B进行灌胃,模型组给予等量生理盐水灌胃,每周 2次,连续 4周。结果：治疗第2周与第4周后,Sal B 1组、Sal B 2组的移植瘤重量均低于模型组(P<0.05),抑瘤率高于模型组(P<0.05),Sal B 1组与Sal B 2组对比差异有统计学意义(P<0.05)。Sal B 1组、Sal B 2组肝脏系数与肝脏表面癌结节数目均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组血清天门冬氨酸氨基转移酶(Aspartate transaminase,AST)、丙氨酸氨基转移酶(Alanine transaminase,ALT)含量均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。Sal B 1组、Sal B 2组肝组织转化生长因子-β1(Transforming growth factor-beta 1,TGF-β1)、Smad3蛋白相对表达水平均低于模型组(P<0.05),Sal B 2组低于Sal B 1组(P<0.05)。结论：Sal B在肝癌荷瘤小鼠中能发挥抑瘤作用,可抑制血清ALT与AST的释放,其可能是通过TGF-β1/Smad3信号发挥抗肝纤维化-肝癌作用。     

数字减影血管造影引导下肝动脉化疗栓塞对肝癌患者肝功能、细胞免疫功能及肿瘤标志物的影响

摘要 目的：探讨数字减影血管造影（DSA）引导下肝动脉化疗栓塞（TACE）对肝癌患者肝功能、细胞免疫功能及肿瘤标志物的影响。方法：随机选取2021年1月～2022年1月来我院就诊的行DSA引导下TACE化疗的肝癌患者50例为研究组,另随机选取同期行常规治疗的肝癌患者50例为对照组,对比两组临床总有效率、肝功能、细胞免疫功能及肿瘤标志物和不良反应情况。结果：研究组的临床总有效率为56.00%（28/50）高于对照组的34.00%（17/50）,差异有统计学意义（P<0.05）。两组治疗结束后谷草转氨酶（AST）和谷丙转氨酶（ALT）升高,但研究组低于对照组（P<0.05）。两组治疗结束后CD8⁺升高,但研究组低于对照组（P<0.05）;CD4⁺、CD4⁺/CD8⁺、CD3⁺均下降,但研究组高于对照组（P<0.05）。两组治疗结束后甲胎蛋白（AFP）、糖链抗原（CA）242、CA724、磷脂酰肌醇蛋白聚糖-3（GPC3）下降,且研究组低于对照组（P<0.05）。对照组（30.00%）、研究组（24.00%）的不良反应发生率组间对比无差异（P>0.05）。结论：DSA引导下TACE化疗治疗肝癌患者,疗效可靠,可有效阻止疾病进展,同时减轻化疗所致的肝损伤和细胞免疫功能损伤。     

人免疫缺陷病毒1型TAT蛋白点突变对其反式激活作用的影响

不同免疫缺陷病毒（ＨＩＶ－１,ＨＩＶ－２和ＳＩＶ）的Ｔａｔ均有３个高度保守的结构域：Ｃｙｓ富集域、核心域和碱性氨基酸富集域,用ＰＣＲ定点突变法在ＨＩＶ－１Ｔａｔ蛋白的这些区域引入单氨基酸或多氨基酸突变;构建了以ＨＩＶ－１ＬＴＲ－１５８到＋８Ｏ区域为启动子,含有不同突变点的突变Ｔａｔ基因表达质粒;以荧光酶基因为报告基因,瞬时共转染Ｊｕｒｋａｔ细胞：分析不同氨基酸突变对Ｔａｔ的反式激活作用的影响。结果发现,突变后的Ｔａｔ蛋白的活性均极大地降低或丧失,表明这些序列内的氨基酸的确定性对Ｔａｔ的活性至关重要。     

柯萨奇B4病毒对小鼠胰岛的影响及干扰素的保护作用

采用我国流行的柯萨奇B4病毒 (CB4V)感染swiss小鼠 ,建立I型糖尿病的动物模型 ,并观察干扰素对CB4V引起的I型糖尿病的保护作用。结果表明 ,80 %的小鼠在感染后 72h出现低血糖 ,血糖在 (90 .87±8.2 6 )mg/L范围之内 ,6～ 8周全部发展为高血糖。糖刺激的胰岛素释放量在感染后 72h增加 ,但至 3～ 8周明显低于正常对照组。在用CB4V感染小鼠的同时给予干扰素 ,目的在于观察干扰素对CB4V攻击胰岛 β细胞的保护作用 ,结果经干扰素治疗后的感染小鼠 ,当给干扰素到 6周 ,80 %小鼠血糖在 (118.6 6± 5 .73)mg/L范围之内 ,而低糖与高糖刺激下的胰岛素释放量分别在 (18.34± 3.5 0 )uIU/mL ,(31.5 1± 4 .71)uIU/mL范围之内 ,均与正常对照组无差异 (p >0 .0 5 )。     

谷氨酰胺联合恩替卡韦对病毒型肝硬化小鼠肝脏病变指标及免疫水平的影响

目的:探讨谷氨酰胺联合恩替卡韦对病毒型肝硬化小鼠肝脏病变指标及免疫水平的影响。方法:将60只健康雄性BABL/cJ小鼠按照随机数字表法分为模型组、谷氨酰胺组,谷氨酰胺联合恩替卡韦组(联合组),对照组,每组15只。采用高压水注射方法将50μL HBV质粒通过尾静脉注入模型组、谷氨酰胺组,联合组三组小鼠体内,然后腹腔注射50%CCI4(5 m L/kg)以构建肝硬化模型小鼠。对照组经尾静脉注射50μL生理盐水,然后腹腔注射生理盐水(5 m L/kg)。谷氨酰胺组接受谷氨酰胺(0.5 m L/10g)治疗,联合组接受恩替卡韦联合谷氨酰胺(0.5 m L/10 g)治疗,对照组、模型组接受生理盐水(0.5 m L/10g)治疗,每天1次,治疗周期均为4周。比较四组小鼠的肝功能、病毒载量、肝纤维化指标、免疫功能。结果:成模后,模型组、谷氨酰胺组、联合组的病毒载量、ALT、AST、HA、PIIIP水平无统计学差异(P0.05);治疗4周后,谷氨酰胺组、联合组两组病毒载量、ALT、AST、HA、PIIIP水平显著下降,且联合组病毒载量、ALT、AST、HA、PIIIP水平低于谷氨酰胺组,差异具有统计学差异(P0.05);治疗4周后,谷氨酰胺组病毒载量、ALT、AST、HA、PIIIP水平低于模型组,差异具有统计学差异(P0.05);治疗4周后,谷氨酰胺组、联合组两组脾脏指数、CD4+、CD4+/CD8+百分率升高组脾脏指数、CD4+、CD4+/CD8+百分率高于谷氨酰胺组,差异具有统计学差异(P0.05)。结论:谷氨酰胺联合恩替卡韦可改善病毒型肝硬化小鼠肝脏肝功能,减轻组织纤维化,并有助于增强其免疫功能。     

慢病毒介导的GFP转染对大鼠骨髓间充质干细胞增殖、细胞表型及脑脊液诱导后分化能力的影响

摘要 目的：研究慢病毒（Lentivirus）介导的绿色荧光蛋白（Lentivirus-GFP）转染大鼠骨髓间充质干细胞（BMSCs）的可行性及稳定性,以及对人脑脊液诱导转染后BMSCs（BMSCs-GFP）成神经分化能力的影响。方法：全骨髓贴壁法培养BMSCs,Lentivirus-GFP以5、10、30、50的感染复数（MOI）转染BMSCs,96h后倒置显微镜下观察GFP转染效率和表达情况,筛选最适MOI;流式细胞术检测细胞表型;CCK8法检测细胞活力。人脑脊液诱导BMSCs-GFP向神经细胞分化,蛋白印迹法检测神经细胞表面标记物MAP-2和Nestin表达。结果：全骨髓贴壁法分离培养的BMSCs生长旺盛。MOI值为5、10、30、50的转染效率分别为56.2%、87.3%、94.7%和95.1%,当MOI为30时,Lentivirus-GFP转染BMSCs效率较高,且对BMSCs生长状态无显著性影响。BMSCs-GFP表达CD29、CD90,较少表达CD45、CD54,符合干细胞特性。BMSCs-GFP增殖活性与未转染GFP基因的BMSCs相比,差异无统计学意义（P>0.05）。人脑脊液诱导BMSCs-GFP成神经细胞分化后表达神经元标记物MAP-2和Nestin。结论：Lentivirus-GFP能高效稳定转染大鼠BMSCs（最适MOI值为30）,同时不影响其生物学特性,人脑脊液能诱导BMSCs-GFP成神经细胞分化。     

口蹄疫重组鸡痘病毒诱导猪特异性细胞毒性T淋巴细胞(CTL)杀伤活性检测

目的:评价口蹄疫重组鸡痘病毒vUTAL3CP1诱导猪产生特异性细胞毒性T淋巴细胞(CTL)杀伤活性的能力。方法:用PCR方法亚克隆O型FMDVVP1基因C末端部分片段(第130～213AA)。将其插入真核表达载体pDisplay中,构建质粒pDisplay-mVP1。将pDisplay-mVP1转染PK15细胞,经3次G418加压筛选,并用RT-PCR和IFA鉴定,证明获得表达目的基因的PK15/pDisplay-mVP1细胞。最后,利用该细胞作为靶细胞,用LDH法检测口蹄疫重组鸡痘病毒vUTAL3CP1免疫猪的特异性CTL杀伤活性。结果:vUTAL3CP1免疫组在效靶比25∶1和50∶1时,CTL裂解活性分别达到42.84%±32.1%和61.94%±42.8%,显著高于灭活疫苗组与其它对照组(p<0.01)。结论:vUTAL3CP1可以诱导猪产生高水平的特异性细胞毒性T淋巴细胞(CTL)杀伤活性,为进一步的FMDV基因工程疫苗的研究奠定了基础。     

Platycodin D2 Improves Specific Cellular and Humoral Responses to Hepatitis B Surface Antigen in Mice

Platycodin D2 ( 1 ), a less hemolytic saponin from the root of Platycodon grandiflorum than platycodin D ( 2 ), was evaluated for the potential to enhance specific cellular and humoral immune responses to hepatitis B surface antigen (HBsAg) in mice. It significantly increased the concanavalin A (Con A)‐, lipopolysaccharide (LPS)‐, and HBsAg‐induced splenocyte proliferation in HBsAg‐immunized mice (P<0.05, P<0.01, and P<0.001, resp.). HBsAg‐specific IgG, IgG1, IgG2a, and IgG2b antibody titers in the serum were also markedly enhanced by 1 compared to the HBsAg control group (P<0.01 or P<0.001). Moreover, 1 significantly promoted the production of Th1 (IL‐2 and IFN‐γ) and Th2 (IL‐4 and IL‐10) cytokines from splenocytes in the HBsAg‐immunized mice (P<0.001). The adjuvant potential of 1 on splenocyte proliferation, serum HBsAg‐specific IgG2a and IgG2b antibody response, as well as Th1‐cytokine secretion from splenocytes in the HBsAg‐immunized mice was higher than that of Alum. The results suggest that 1 could improve both cellular and humoral immune responses to HBsAg in mice. Hence, 1 might be a promising adjuvant for hepatitis B vaccine with dual Th1‐ and Th2‐potentiating activity.     

Induction of humoral and cellular immune responses in mice by a recombinant fowlpox virus expressing the E2 protein of bovine viral diarrhea virus

A recombinant fowlpox virus (rFPV/E2) expressing the E2 protein of bovine viral diarrhea virus (BVDV) was constructed and characterized. Mice were immunized with recombinant virus and both humoral and cellular immune responses were studied. rFPV/E2 induced BVDV-specific antibodies which were detected by ELISA. In addition, mouse sera were shown to neutralize BVDV. A cytokine ELISA assay revealed that mice vaccinated with rFPV/E2 induced 7-fold more interferon-gamma than parental fowlpox virus.     

HCV/HBV复合抗原基因的克隆、表达及免疫应答研究

为探讨ＨＣＶ／ＨＢＶ 复合疫苗的可行性,将合成的丙型肝炎病毒（ＨＣＶ）复合多表位抗原基因ＰＣＸ与ＨＢｓＡｇ 基因连接成ＰＣＸＳ基因,与β－半乳糖苷酶（ＧＺ）基因融合后在大肠杆菌及减毒鼠伤寒沙门氏菌中获得表达．目的蛋白ＧＺ－ＰＣＸＳ可被抗－ＨＢｓ 及抗－ＨＣＶ 抗体所特异识别．ＧＺ－ＰＣＸＳ抗原皮下注射免疫ＩＣＲ小鼠后,诱发了较高水平的抗－ＧＺ－ＰＣＸＳＩｇＧ反应．构建的重组减毒鼠伤寒沙门氏菌ＳＬ３２６１（ｐＷＲ／ＰＣＸＳ）口服免疫小鼠后,诱发了高水平的ＣＤ８＋ Ｔ细胞增殖反应及抗ＧＺ－ＰＣＸＳＩｇＧ反应．所有免疫小鼠均未见明显的毒副作用．该研究揭示,ＨＣＶ／ＨＢＶ 复合抗原可诱发特异性体液免疫及细胞免疫应答,而活菌苗口服可能是理想的免疫途径,为ＨＣＶ／ＨＢＶ 双价疫苗研究提供了一定的理论及实验依据．     

Acetylcholine Synthesis and Release by a Sympathetic Ganglion in the Presence of 2-(4-Phenylpiperidino) Cyclohexanol (AH5183)

These experiments measured the release and the synthesis of acetylcholine (ACh) by cat sympathetic ganglia in the presence of 2-(4-phenylpiperidino) cyclohexanol (AH5183), an agent that blocks the uptake of ACh into synaptic vesicles. Evoked transmitter release during short periods of preganglionic nerve stimulation was not affected by AH5183, but release during prolonged stimulation was not maintained in the drug's presence, whereas it was in the drug's absence. The amount of ACh releasable by nerve impulses in the presence of AH5183 was 194 +/- 10 pmol, which represented 14 +/- 1% of the tissue ACh store. The effect of AH5183 on ACh release was not well antagonized by 4-aminopyridine (4-AP), and not associated with inhibition of stimulation-induced calcium accumulation by nerve terminals. It is concluded that AH5183 blocks ACh release indirectly, and that the proportion of stored ACh releasable in the compound's presence represents transmitter in synaptic vesicles available to the release mechanism. The synthesis of ACh during 30 min preganglionic stimulation in the presence of AH5183 was 2,448 +/- 51 pmol and in its absence it was 2,547 +/- 273 pmol. Thus, as the drug decreased ACh release it increased tissue content. The increase in tissue content of ACh in the presence of AH5183 was not evident in resting ganglia; it was evident in stimulated ganglia whether or not tissue cholinesterase was inhibited; it was increased by 4-AP and reduced by divalent cation changes expected to decrease calcium influx during nerve terminal depolarization.(ABSTRACT TRUNCATED AT 250 WORDS)     

IL-12增强HBV融合抗原DNA疫苗在小鼠诱导的细胞免疫应答

乙型肝炎病毒(hepatitis B virus,HBV)极易形成慢性感染,主要机制在于感染者不能产生强有力的细胞免疫应答以清除病毒[1].慢性HBV感染者体内虽然存在HBV抗原特异性T淋巴细胞,但对HBV抗原的反应性较低.研究发现,增强这类T淋巴细胞的反应性,可以促进HBV的清除[2].     

The Interferon-induced Transmembrane Proteins,IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry

The interferon-induced transmembrane (IFITM) family of proteins have recently been identified as important host effector molecules of the type I interferon response against viruses. IFITM1 has been identified as a potent antiviral effector against hepatitis C virus (HCV), whereas the related family members IFITM2 and IFITM3 have been described to have antiviral effects against a broad range of RNA viruses. Here, we demonstrate that IFITM2 and IFITM3 play an integral role in the interferon response against HCV and act at the level of late entry stages of HCV infection. We have established that in hepatocytes, IFITM2 and IFITM3 localize to the late and early endosomes, respectively, as well as the lysosome. Furthermore, we have demonstrated that S-palmitoylation of all three IFITM proteins is essential for anti-HCV activity, whereas the conserved tyrosine residue in the N-terminal domain of IFITM2 and IFITM3 plays a significant role in protein localization. However, this tyrosine was found to be dispensable for anti-HCV activity, with mutation of the tyrosine resulting in an IFITM1-like phenotype with the retention of anti-HCV activity and co-localization of IFITM2 and IFITM3 with CD81. In conclusion, we propose that the IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation and demonstrate that the actions of the IFITM proteins are indeed virus and cell-type specific.     

In Vitro Modification of Human Immunodeficiency Virus Type 1 (HIV-1) Infectivity by the U937 Cells

The effect of host cell factors on infectivity of human immunodeficiency virus type 1 (HIV-1) was studied by infecting a monoblastoid cell line (U937) or a T-cell line (MOLT-4) with a highly infective single clone of HIV-1 and comparing the infectivity of the produced viruses to different cell lines. Chronically infected U937 cells consistently produced viruses with minimal infectivity. This phenotypic change was host-dependent as the back-passage of the U937-produced low infective viruses into MOLT-4 cells resulted in regaining their original high infectivity. Southern and Northern blot analyses of the HIV-1 grown in U937 cells did not reveal any genomic difference between it and the virus grown it MOLT-4 cells. The radioimmunoprecipitation analysis of viral proteins showed that the HIV-1-infected U937 cells had a different pattern of envelope glycoproteins and core proteins, which well correlated with the low infectivity of the produced viruses. This experimental system using MOLT-4 and U937 cell lines would be useful to further explore host cell factor(s) which play an important role in the regulation of HIV-1 infectivity.     

Acetylcholine Mobilization in a Sympathetic Ganglion in the Presence and Absence of 2-(4-Phenylpiperidino)Cyclohexanol (AH5183)

The present experiments measured the release of acetylcholine (ACh) by the cat superior cervical ganglia in the presence of, and after exposure to, 2-(4-phenylpiperidino)cyclohexanol (AH5183), a compound known to block the uptake of ACh by cholinergic synaptic vesicles. We confirmed that AH5183 blocks evoked ACh release during preganglionic nerve stimulation when approximately 13-14% of the initial ganglial ACh stores had been released; periods of rest in the presence of the drug did not promote recovery from the block, but ACh release recovered following the washout of AH5183. ACh was synthesized in AH5183-treated ganglia, as determined by the synthesis of [3H]ACh from [3H]choline, and this [3H]ACh could be released by stimulation following drug washout. The specific activity of the released ACh matched that of the tissue's ACh, and thus we conclude that ACh synthesized in the presence of AH5183 is a releasable as pre-existing ACh stores once the drug is removed. We tested the relative releasability of ACh synthesized during AH5183 exposure (perfusion with [3H]choline) and that synthesized during recovery from the drug's effects (perfusion with [14C]choline: the ratio of [3H]ACh to [14C]ACh released by stimulation was similar to the ratio in the tissue. These results suggest that the mobilization of ACh for release by ganglia during recovery from an AH5183-induced block is independent of the conditions under which the ACh was synthesized. Unlike nerve impulses, black widow spider venom (BWSV) induced the release of ACh from AH5183-blocked ganglia, even in the drug's continued presence. Venom-induced release of ACh from AH5183-treated ganglia was not less than the venom-induced release from tissues not exposed to AH5183. This effect of BWSV was attributed to the action of the protein, alpha-latrotoxin, because an anti-alpha-latrotoxin antiserum blocked the venom's action. ACh synthesized during AH5183 exposure was labelled from [3H]choline, and subsequent treatment with BWSV released [3H]ACh with the same temporal pattern as the release of total ACh. To exclude a nonexocytotic origin for the [3H]ACh released by BWSV, ganglia were preloaded with [3H]diethylhomocholine to form [3H]acetyldiethylhomocholine, an ACh analogue excluded from vesicles; the venom did not increase the rate of [3H]acetyldiethylhomocholine efflux. It is concluded that a vesicular ACh pool insensitive to the inhibitory action of AH5183 might exist and that this vesicular pool is not mobilized by electrical stimulation to exocytose in the presence of AH5183, but it is by BWSV.     

含半胱氨酸的天冬氨酸蛋白水解酶(caspase-1)对猪伪狂犬病毒复制的影响

猪伪狂犬病是伪狂犬病毒(Pseudorabies virus,PRV)感染引起的一种烈性接触性传染病,其感染宿主会触发机体先天免疫应答,引起I型干扰素(Type I interferon,IFN-1)和炎性细胞因子等细胞因子的产生,为研究可诱导产生炎性细胞因子的含半胱氨酸的天冬氨酸蛋白水解酶(Cysteinyl aspartate specific proteinase 1,caspase-1)的基因敲除对PRV复制的影响,本试验利用近年来发展迅速的一项规律性短重复回文序列簇/Cas9核酸酶(Clustered regulatory interspaced short palindromic repeat/CRISPR associated system 9,CRISPR/Cas9)基因定点修饰技术构建猪肾上皮细胞(Porcine kidney epithelial cells,PK15)caspase-1基因稳定敲除细胞系,并通过T7核酸酶检测敲除效率;细胞毒性(Cell counting kit-8,CCK-8)试剂盒检测PK15敲除caspase-1增殖影响;采用流式细胞术检测PRV-GFP感染PK15以及PK15-caspase-1^-/-的增殖差异;实时荧光定量PCR(Real-time quantitative PCR,RT-PCR)检测PRV-gB、TK及白细胞介素1β(Interleukin-1β,IL-1β)、IFN-β、干扰素刺激基因(Interferon-stimulated genes 20,ISG20)mRNA的表达;Western Blot检测PRV-gB蛋白表达;滴度测定检测子代病毒滴度。结果表明,2对特异性单链引导RNA(Single guide RNA,sgRNA)均能对caspase-1进行基因编辑,但经T7核酸酶酶切进行基因编辑效率分析结果表明sgRNA2的基因编辑效率较高;CCK-8试剂盒检测细胞活力结果表明caspase-1基因敲除对PK15以及PK15-caspase-1^-/-细胞活力无影响(P>0.05);流式细胞仪检测结果表明PRV-GFP在PK15-caspase-1^-/-中的增殖显著低于PK15细胞(P<0.05);定量RT-PCR结果表明PRV-gB、TK基因在PK15-caspase-1^-/-的mRNA表达显著低于PK15细胞(gB:P<0.05,TK:P<0.05),而IFN-β、ISG20基因在PK15-caspase-1^-/-的mRNA表达显著高于PK15细胞(gB:P<0.05,TK:P<0.05);Western Blot结果表明,PRV的gB蛋白在PK15-caspase-1^-/-的表达显著低于PK15细胞(P<0.05);滴度测定结果表明,敲除caspase-1能够抑制PRV子代病毒的增殖。以上结果均表明caspase-1基因敲除可抑制PRV在PK15细胞中复制。